Sernova Corp. is developing Cell Pouch and Sertolin platform technologies using a tiered approach. The Company is focusing on initiating human clinical trials of the Cell Pouch for therapeutic cell transplantation using autograft (self-cells) or allograft (donor human cells) with an anti-rejection protocol. The Cell Pouch is an implantable medical device placed under the skin with chambers for therapeutic cell transplantation. The Company is focused on the use of insulin-producing islets for treatment of patients who have diabetes. The Company�s technologies the Cell Pouch System used in patients who are planning on having an allograft transplant as an alternative to injecting islets into the portal vein of the liver. The patients with the Cell Pouch who have had an allograft transplant may be given either anti-rejection therapy or could be given Sertolin from a human source to reduce or eliminate the need for anti-rejection drugs.